Aptevo Therapeutics Inc. (APVO): Price and Financial Metrics

Aptevo Therapeutics Inc. (APVO)

Today's Latest Price: $5.56 USD

0.14 (-2.46%)

Updated Jun 1 9:39am

Add APVO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

APVO Stock Summary

  • With a year-over-year growth in debt of -86.76%, Aptevo Therapeutics Inc's debt growth rate surpasses just 2.21% of about US stocks.
  • In terms of volatility of its share price, APVO is more volatile than 99.66% of stocks we're observing.
  • Aptevo Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 121.06%, greater than the shareholder yield of 96.72% of stocks in our set.
  • Stocks that are quantitatively similar to APVO, based on their financial statements, market capitalization, and price volatility, are ADTN, OIIM, MNDO, PGNX, and MOSY.
  • APVO's SEC filings can be seen here. And to visit Aptevo Therapeutics Inc's official web site, go to www.aptevotherapeutics.com.
APVO Daily Price Range
APVO 52-Week Price Range

APVO Stock Price Chart More Charts

APVO Price/Volume Stats

Current price $5.56 52-week high $14.56
Prev. close $5.70 52-week low $2.94
Day low $5.53 Volume 5,287
Day high $5.78 Avg. volume 96,428
50-day MA $4.73 Dividend yield N/A
200-day MA $7.38 Market Cap 17.98M

Aptevo Therapeutics Inc. (APVO) Company Bio

Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.

APVO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

APVO Latest Social Stream

Loading social stream, please wait...

View Full APVO Social Stream

Latest APVO News From Around the Web

Below are the latest news stories about Aptevo Therapeutics Inc that investors may wish to consider to help them evaluate APVO as an investment opportunity.

Aptevo Therapeutics Reports First Quarter 2020 Financial Results

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potential ...

Yahoo | May 13, 2020

Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRâ„¢ bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

Yahoo | April 14, 2020

Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update

Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosing ...

Yahoo | March 25, 2020

Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial

At present, dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly. No evidence of dose-limiting toxicities was observed in the latest dose cohort (cohort 5.) A dose-limiting toxicity was observed in 1 of 6 patients in cohort 4.

Yahoo | March 16, 2020

The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ...

Benzinga | March 13, 2020

Read More 'APVO' Stories Here

APVO Price Returns

1-mo 5.90%
3-mo 2.91%
6-mo -36.96%
1-year -45.22%
3-year -81.61%
5-year N/A
YTD -39.32%
2019 -48.46%
2018 -70.05%
2017 73.77%
2016 N/A
2015 N/A

Continue Researching APVO

Here are a few links from around the web to help you further your research on Aptevo Therapeutics Inc's stock as an investment opportunity:

Aptevo Therapeutics Inc (APVO) Stock Price | Nasdaq
Aptevo Therapeutics Inc (APVO) Stock Quote, History and News - Yahoo Finance
Aptevo Therapeutics Inc (APVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9924 seconds.